Merck & Co Inc

NYSE: MRK
$99.18
-$0.68 (-0.7%)
Closing Price on November 22, 2024

MRK Articles

The September 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Merck has just announced that the FDA has accepted a couple new drug applications for review, including for a treatment for Clostridium difficile infections in children.
These four top large-cap pharmaceutical stocks for investors to consider all pay solid dividends and look like very solid fourth-quarter ideas.
The September 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
These four outstanding ideas from the US 1 team at Merrill Lynch are decidedly more conservative than most of the list's holdings, but they offer investors excellent total return potential and a...
NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and granted priority review for the investigational Ebola...
As, when and if ESG themes continue to gain in popularity, imagine what could happen to some of the top-ranked ESG companies. Imagine also what could happen to some of the companies that are...
The August 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and initiations on Friday included Alibaba, Amgen, Applied Materials, Intel, Merck, Nvidia and Walmart.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and initiations seen on Wednesday included Arconic, Boston Beer, Dunkin' Brands, DuPont, GreenSky, International Flavors & Fragrances, Merck and Walt Disney.
Merck released better than expected second-quarter financial results before the markets opened on Tuesday.
Pfizer and Merck are each scheduled to release their second-quarter financial results early Tuesday. These are just a couple of the Dow Jones industrials that are reporting this week, but they make...